HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe

Sleep Market Growth Slowing, Short-Term Rebound Unlikely

February 21, 2008 by HME Business

Wachovia Capital Markets says that growth in the global sleep market has slowed, and that while home sleep testing should eventually drive faster growth it still faces some obstacles.

Wachovia estimates that the global sleep market grew by 13 percent constant currency (cc) in the December quarter, down from 14.5 percent cc in the September quarter. Over the next 12 months, respondents to Wachovia’s Q1 2008 Sleep Center Survey say they plan to expand their bed capacity by 13 percent and expect 10 percent patient volume growth.

Based on these data points, Wachovia has lowered its forecast for global sleep market growth in 2008 to 14 to 16 percent cc from its prior forecast of 16 to 18 percent cc.

Where home sleep testing is concerned, Wachovia says it expects home sleep testing to drive faster U.S. sleep market growth and push the U.S. market closer to 20 percent by mid-2009 assuming that Medicare’s final decision is not too restrictive. Wachovia says some of its contacts have suggested that CMS might attempt to limit home testing to sleep physicians or accredited sleep labs in its final decision, due on March 14.

Such a restriction could limit the positive impact of home testing. And even in the best case, Wachovia says it would take 12 months or longer after the final decision before the industry would see a significant impact from home testing on U.S. growth.

Related Articles Read More >

NCPA Announces New Senior Vice President of the Office of CEO
Sara Roszak is an industry veteran who most recently served at the National Association of Chain Drug Stores.
More HCPCS Codes to Be Added to Medicare Prior Authorization Process in October
Prior authorization will be required for eight additional codes for dates of service of Oct. 28 and later.
M&A Update, Part 2: What Makes a Good Investment or Acquisition?
At the HME Business FUTURE conference, experts on mergers and acquisitions took the stage.
Frazier Healthcare Acquires MatrixCare, Appoints CEO
MatrixCare was owned by Resmed.

Get the free newsletter

Home Healthcare Softare

Subscribe to HME Business for industry & product news, trends and resources.
HME Business Directory
HME Podcasts
HME Business
  • Mobility Management
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • About HME Business
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe